Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Adagrasib + MRTX0902 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Adagrasib | Krazati | MRTX849|MRTX-849|MRTX 849 | KRAS G12C inhibitor 33 | Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov). |
MRTX0902 | MRTX-0902|MRTX 0902 | SOS1 Inhibitor 13 | MRTX0902 inhibits SOS1, blocking interaction with Kras and potentially reducing tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND02). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Recruiting | USA | 1 |